Compare Summit Therapeutics Inc (SMMT) vs TE Connectivity plc Ordinary Shares (TEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs TE Connectivity plc Ordinary Shares — how do they compare? Summit Therapeutics Inc trades at $17.27 (market cap $14.33B), while TE Connectivity plc Ordinary Shares trades at $214.01 (market cap $62.49B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 4.4× Summit Therapeutics Inc's market cap, and TE Connectivity plc Ordinary Shares pays a 1.45% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TEL | |
|---|---|---|
Market Cap | $14.33B | $62.49B |
Volume | 8,167,213 | 1,845,947 |
Sector | Health | Technology |
52-Week High | $26.38 | $249.00 |
52-Week Low | $12.43 | $195.84 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $13.66B | $66.88B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.95, up 3.7% today, with a bullish technical signal from moving averages and a consensus analyst price target of $29.33. The stock has surged recently following a $2 billion strategic equity investment from AstraZeneca and expanded clinical collaborations. However, the company remains pre-revenue with significant losses, reflected in a negative ROE of -192.5% and negative EBITDA of -$1.08 billion for 2025.
The outlook is driven by clinical progress for ivonescimab, but high execution risk and cash burn necessitate close monitoring. Investment opportunity hinges on successful drug development, while key risks include trial outcomes and funding needs. The stock offers high-risk, high-reward potential based on pipeline milestones.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →
